Fosamax Osteonecrosis of the Jaw Causation: Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Communication to Focused Exposure Assessment

General health and science communication has long served as a bridge between complex biomedical information and public understanding, emphasizing prevention, risk awareness, and informed decision-making. Within this legacy, discussions of medication safety and adverse effects have been framed in broad, accessible terms—highlighting the importance of monitoring, patient education, and cautious prescribing. This foundational approach has proven valuable for translating emerging safety signals into actionable guidance for both clinicians and the general population. As this communication framework evolves, it naturally extends to more specific exposure contexts, including occupational and therapeutic settings where sustained contact with certain agents may elevate risk. The transition from general health discourse to focused exposure assessment requires careful attention to the pathways through which individuals encounter potential hazards. In the case of bisphosphonate therapy, the shift involves moving from population-level safety messaging to examining how prolonged pharmacological exposure—particularly in patients receiving high cumulative doses—may intersect with oral health outcomes. This pivot does not presuppose causation but rather establishes a structured inquiry into whether a temporal or dose-related association exists between the medication and reported jaw complications. By maintaining the neutral, evidence-informed tone of general health communication, this transition enables a rigorous exploration of exposure-risk relationships without premature mechanistic conclusions.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the general framework of medication safety, we now focus specifically on Fosamax (alendronate sodium), a bisphosphonate approved for osteoporosis and other bone conditions. The question of whether Fosamax causes osteonecrosis of the jaw (ONJ) is addressed through clinical reports, mechanistic understanding, and risk factor analysis. Clinical evidence from the FDA-approved labeling indicates that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling explicitly states that osteonecrosis of the jaw has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This establishes a documented association between Fosamax exposure and ONJ occurrence, though the labeling notes that in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a reported adverse event, its incidence in controlled trials was not significantly elevated compared to placebo, indicating that other factors may contribute.

Mechanistic Pathways and Risk Factors

Mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacology as a bisphosphonate that inhibits bone resorption. Bisphosphonates accumulate in bone, particularly in areas of high turnover such as the jaw, and can suppress osteoclast activity, leading to reduced bone remodeling and impaired healing after dental procedures (https://pubmed.ncbi.nlm.nih.gov/40345077/). The multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This mechanistic insight supports a causal pathway where Fosamax alters normal bone turnover in the jaw, increasing vulnerability to ONJ, especially when combined with local trauma or infection. Risk factors for ONJ in patients taking Fosamax are well-documented. Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This indicates that the risk is modifiable and that clinical management can mitigate harm.

Temporal Association and Adequacy of Warnings

The timeline between exposure and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship, as symptoms are temporally associated with exposure and can recur upon re-exposure. Adequacy of warnings regarding Fosamax and ONJ is addressed in the labeling. The warnings and precautions section explicitly includes osteonecrosis of the jaw as a reported adverse event, with detailed risk factors and management recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The labeling advises discontinuation if severe symptoms develop and notes that most patients had relief after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the labeling also states that in placebo-controlled studies, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may create ambiguity about the strength of causation. For affected patients, causation considerations include the presence of other risk factors, duration of therapy, and temporal relationship. The labeling provides guidance for clinicians to assess risk and consider discontinuation before invasive dental procedures.

Summary of Evidence

In summary, evidence supports that Fosamax is associated with ONJ, with a plausible mechanistic pathway through bisphosphonate-induced suppression of bone remodeling in the jaw. The risk is increased by duration of exposure and co-existing risk factors such as dental procedures and comorbidities. Warnings in the labeling are present but may be nuanced by clinical trial data showing similar incidence to placebo. For patients, the timeline of onset can be rapid, and symptoms often resolve with discontinuation, though recurrence upon rechallenge indicates a drug-specific effect.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the association between Fosamax and osteonecrosis of the jaw?

Clinical evidence from FDA-approved labeling indicates that osteonecrosis of the jaw (ONJ) has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in placebo-controlled studies, the incidence was similar between Fosamax and placebo groups, suggesting other factors may contribute (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Known risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Can stopping Fosamax reduce the risk of ONJ?

Yes, for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Most patients have relief of symptoms after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.